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Abstract 
In several countries in southern Africa, including South Africa, the prevalence of HIV remains 
stubbornly high in spite of considerable efforts to reduce transmission and to provide anti-retroviral 
therapy (ART).  It is important to know the extent to which the high prevalence of HIV reflects the 
increasing number of people on ART in which case the prevalence of those not on ART may be 
falling. Unfortunately, direct measures of the proportion of HIV-positive people who are on ART are 
lacking in most countries and we need to use dynamical models to estimate the impact of ART on the 
prevalence of HIV. In this paper we show that the current level of ART provision in South Africa has 
probably reduced the prevalence of HIV among those not on ART by 1.9 million, averted 259 
thousand new infections and 428 thousand deaths. 
 
Introduction 
South Africa has one of the worst epidemics of HIV 
in the world,1 but has the best surveillance system2-5 
and now one of the highest levels of ART 
provision.1 
 In some countries, including most notably 
Zimbabwe,6 HIV prevalence is falling. While it 
must be the case that people’s behaviour has 
changed, the reasons for this are not immediately 
apparent. In South Africa, on the other hand, the 
prevalence of HIV among women attending ante-
natal clinics has been stable for several years with 
no sign of a decline.7 Here we ask, in relation to 
South Africa in particular, what is the likely impact 
of ART on the incidence, prevalence and mortality 
of HIV in South Africa? 
Methods 
In the absence of direct empirical data we rely on 
modelling the impact of ART on the HIV epidemic. 
We fitted a previously published model8 to trend 
data on HIV prevalence from the annual ante-natal 
clinic (ANC) surveys, scaled to reflect the rates in 
the overall adult population aged 15 years or more.8 
The model includes four stages of HIV-infection, 
with equal rates of progression between them, 
which gives a good approximation to a Weibull 
distribution with a mean survival time of 11.5 years 
and a shape parameter of 2.25.9 We use ART 
coverage data for South Africa reported by WHO 
and UNAIDS.1 Given that the mean CD4+ cell 
count in young adults in South Africa, immediately 
after seroconversion, is about 800/μL,10 Stage 4 
corresponds to people with a CD4+ cell count 
between 0 and 200/μL. We assume that everyone 
starts ART in Stage 4.11  We also assume that 
people starting ART will extend their life 
expectancy by a factor of 4 depending on the stage 
they are in when they start treatment.12 The median 
life-expectancy of those entering Stage 4 will 
therefore increase from 2.9 years to 11.5 years. This 
is  consistent with recent data for people starting 
ART at very low CD4+ cell counts among whom 
there is 80% to 90% survival at 5 years even among 
those starting ART at a CD4+ cell count of 15/μL.13  
Results 
Figure 1A shows the model fitted to the current 
estimates of HIV prevalence (blue dots) and the 
projected HIV incidence (green line), prevalence 
(blue line) and deaths (black line) if we assume that 
ART had never been provided and people had not 
changed their behaviour.   
 In Figure 1B, the proportion of people in ART 
(pink line) increases logistically with the 
parameters chosen to give the best fit to the ART 
data (pink dots). We allow the coverage of ART to 
increase until 2020, as shown in the Figure. 
Projections into the future will depend on 
assumptions about the extent to which ART 
coverage continues to increase and on the life-
expectancy after starting ART. 
 The modelled prevalence of HIV, including 
those on and off ART, matches the measured data 
quite precisely in both cases. However, Figure 1B 
suggests that there has been a significant decline in 
the prevalence of HIV among those not on ART 
(red line) while those on ART (pink line) will live 
for another ten years and possibly more. Indeed the 
model suggests that the ART programme in South 
Africa has already reduced the prevalence of HIV 
among those not on ART by 1.9 million, has 
averted 259 thousand new infections and 428 
thousand deaths. Maintaining and slightly 
expanding the current level of treatment up to 2010 
will reduce the prevalence of HIV in those not on 
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treatment by a further 1.4 million, avert and 
additional 1.3 million new infections and 1.3 
million deaths. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. A: Adult prevalence (blue), annual incidence (green) 
and mortality (black) fitted to the trend in the prevalence of 
HIV in South Africa (blue dots and error bars) assuming that 
ART had not been provided. B: As in A but with the prevalence 
of HIV in people not on ART (red), on ART (pink), and the 
annual mortality of people not on ART (black) and on ART 
(grey).  Proportion of people receiving ART (pink dots). 
 It is important to note that while starting people 
in South Africa on ART when their CD4+ cell 
count is below 200/μL reduces the steady mortality 
by a factor of 3.3, from 1.3% p.a. to 0.4% p.a., it 
only reduces incidence by a factor of 1.5, from 
1.6% p.a. to 1.1% p.a. To further reduce incidence 
as well as mortality it will be necessary to start 
ART at higher CD4+ cell counts and to eliminate 
HIV transmission people need to start ART within 
one year of sero-conversion.8 
Discussion 
The roll-out of ART in South Africa has had, and 
will continue to have, a substantial impact on the 
epidemic of HIV, reducing the death-toll from 
AIDS by 1.7 million over the next 20 years. 
However, the ultimate arbiter of science is not the 
authority of scientists or the quality of theoretical 
models; rather it lies in actual data, carefully 
measured, collected and analyzed. What models 
can do is tell us what more we need to know. In 
particular, it would be of great value if, in the next 
ANC survey in South Africa, blood samples of HIV 
positive cases were both used to estimate HIV 
incidence14 and tested for ART residues. This 
would allow us to make better estimates of the 
actual and predicted impact of the ART roll-out on 
prevalence and incidence, and give us much greater 
confidence in what seems to us to be a significant 
achievement in slowing down the epidemic of HIV.  
It would also help to improve our model predictions 
and inform us on the best way to bring the epidemic 
to an end.  
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